Holen Sie sich die Stockscreener-App
8.12
4.37%
0.34
Handel nachbörslich:
8.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
SLS Stock Heads For Their Best Month This Year Ahead Of Key AML Trial Readout - Yahoo Finance
What’s Fueling SLS Stock? Delayed AML Trial Readout, A Knicks Analogy, And A 185% Rally This Year - Stocktwits
SLS Stock Rallies After Hours As CEO Teases Leukemia Study Data Any Day Now - Stocktwits
SLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readout - MSN
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Tanks Hard: Retail Traders Blame Warrant Holders, 'Flippers' Cashing Out Before AML Catalyst - Stocktwits
Why did ARM, SLS, EBAY stocks surge to 52-week highs? - MSN
SLS stock tanks hard: Retail traders blame warrant holders, 'flippers' cashing out before AML catalyst - MSN
SLS stock pops big after hours on imminent leukemia trial data readout optimism - MSN
SLS stock rallies after hours as CEO teases leukemia study data any day now - MSN
NBIS, CSCO, SLS stocks hit 52-week highs today: What's behind the surge? - MSN
SLS stock hits over 4-year high: CEO eyes FDA talks, ‘whole gamut’ of cancer uses for GPS - MSN
Sellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish Signal (NASDAQ:SLS) - Seeking Alpha
Assessing SELLAS Life Sciences Group (SLS) Valuation After Strong Multi-Year Returns And A Sharp One-Day Share Price Drop - simplywall.st
SLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomes - MSN
SELLAS Life Sciences Group Down Nearly 19%, on Pace for Largest Percent Decrease Since March 2024 -- Data Talk - Moomoo
SLS Stock Pulls Back As Cash Pile Extends Biotech Runway - StocksToTrade
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Why Did ARM, SLS, EBAY Stocks Surge To 52-Week Highs? - Stocktwits
SLS: Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials - TradingView
SLS Stock Jumps As Cash Pile Grows And Trial Catalysts Near - StocksToTrade
SLS Stock Jumps As SELLAS Boosts Cash And Near-Term Catalysts - timothysykes.com
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move? - Benzinga
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus - TechStock²
SLS: Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts - TradingView
SLS: GPS and SLS-009 advance in AML, with pivotal data and biomarker-driven expansion expected soon - TradingView
SLS Technical Analysis | Trend, Signals & Chart Patterns | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earnings - MSN
SLS Stock Price, Quote & Chart | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill
SELLAS Life Sciences (SLS) Nears Pivotal AML Data as Cash, Pipeline and ATM Plan Reframe Its Story - simplywall.st
SLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readout - MSN
SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN
SELLAS Life Sciences Group, Inc.Common Stock (NQ: SLS - FinancialContent
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade - MSN
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
SLS stock surges into conference season as investors hunt for AML readout hints - MSN
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):